Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Neurogene Inc(NGNE)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for NGNE
09/28/2026: NGNE (1-star) is currently NOT-A-BUY. Pass it for now.
Neurogene Inc is a clinical-stage biotechnology company focused on developing proprietary gene therapies for rare, complex neurological disorders. Its primary strength lies in a specialized delivery platform designed to improve therapeutic safety and expression, targeting conditions with high unmet needs. The company's growth story centers on the successful clinical advancement of its lead candidates, NGN-401 and NGN-101. Investors must balance this potential against significant execution, financial, and clinical risks typical of early-stage biotech, including the lack of revenue and potential dilution. Neurogene is best suited for growth-oriented investors with high risk tolerance who monitor binary clinical developments and regulatory outcomes closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high growth potential dependent on clinical success rather than established revenue streams. |
| Momentum investor | Mixed fit | Momentum may be driven by clinical trial catalysts and binary events typical of small-cap biotech stocks. |
| Value investor | Weak fit | The lack of earnings and early-stage status makes traditional valuation metrics difficult to apply. |
| Dividend investor | Weak fit | The company does not pay dividends and is in a capital-intensive phase. |
| Low-risk investor | Weak fit | High clinical, regulatory, and financial risk profiles are unsuitable for risk-averse investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks often experience sharp fluctuations based on trial results and regulatory updates. |
| Valuation risk | High | As there is no commercial revenue, valuation is highly sensitive to market sentiment and future success projections. |
| Competition risk (Gene therapy space) | Medium / high | Multiple companies are developing therapies for rare neurological conditions, increasing pressure for successful outcomes. |
| Business quality | Medium | The business relies on a proprietary platform, but its quality remains unproven at the commercial scale. |
| Dividend income | Low / none | Investors should not expect income, as capital is directed toward R&D. |
| Execution risk | High | Successful clinical development and navigation of regulatory pathways are critical for business survival. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -48.52% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 569.92M USD | Price to earnings Ratio - | 1Y Target Price 80.43 |
Price to earnings Ratio - | 1Y Target Price 80.43 | ||
Volume (30-day avg) 296.7K shares | Beta 1.96 | 52 Weeks Range 15.93 - 43.66 | Updated Date 09/28/2026 |
52 Weeks Range 15.93 - 43.66 | Updated Date 09/28/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.07 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Gene Therapy R&D | Clinical trial programs for NGN-401 and NGN-101. | The company is not yet selling products; revenue depends on future FDA approvals and successful commercialization. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 402.31M | Price to Sales(TTM) 438.73 |
Enterprise Value 402.31M | Price to Sales(TTM) 438.73 | ||
Enterprise Value to Revenue 480.94 | Enterprise Value to EBITDA -8.02 | Shares Outstanding 20.01M | Shares Floating 11.33M |
Shares Outstanding 20.01M | Shares Floating 11.33M | ||
Percent Insiders 6.98 | Percent Institutions 88.93 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Neurogene Inc
Exchange NASDAQ | Headquarters New York, NY, United States | ||
IPO Launch date 2014-03-07 | Founder, Executive Chair & CEO Dr. Rachel L. McMinn Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 131 | Website https://www.neurogene.com |
Full time employees 131 | Website https://www.neurogene.com | ||
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.